4D Molecular Therapeutics officer plans $1.2M sale

Accepted by SEC EDGAR 06/22/2026 - 05:58 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. (FDMT) is named in a Form 144 notice for a proposed sale by its officer, David Kirn, of 114,746 Class A Common shares. The notice lists an approximate sale date of June 22, 2026, and an aggregate market value of $1,195,653.32.

The notice also lists a June 1, 2026 sale of 1,922 shares for gross proceeds of $19,257.86. Goldman Sachs & Co. LLC is named as broker. The proposed sale is connected with a selling plan dated January 9, 2026, intended to comply with Rule 10b5-1(c).

Key Figures

Proposed sale: 114,746 shares Aggregate market value: $1,195,653.32 Shares outstanding: 52,276,254 shares +3 more

6 metrics

Proposed sale 114,746 shares Class A Common; approximate sale date June 22, 2026

Aggregate market value $1,195,653.32 Proposed sale

Shares outstanding 52,276,254 shares Number listed in the notice

Recent sale 1,922 shares Sale on June 1, 2026

Gross proceeds $19,257.86 Sale on June 1, 2026

Selling plan date January 9, 2026 Plan connected with the proposed sale

Key Terms

Rule 10b5-1(c), Aggregate Market Value, Class A Common

3 terms

Rule 10b5-1(c) regulatory

"intended to comply with Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Class A Common financial

"Class A Common"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many FDMT shares does David Kirn plan to sell?

The notice lists a proposed sale of 114,746 Class A Common shares, with an approximate sale date of June 22, 2026 and an aggregate market value of $1,195,653.32.

Is David Kirn's proposed FDMT sale connected with a Rule 10b5-1 plan?

Yes. The notice says the proposed sale is connected with a selling plan dated January 9, 2026, intended to comply with Rule 10b5-1(c).

What recent FDMT sale by David Kirn does the notice list?

It lists a sale of 1,922 shares on June 1, 2026, for gross proceeds of $19,257.86.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001834021
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	4D Molecular Therapeutics, Inc.
SEC File Number	001-39782
Address of Issuer	5858 Horton Street Suite 455 Emeryville CALIFORNIA 94608
Phone	1-510-505-2680
Name of Person for Whose Account the Securities are To Be Sold	David Kirn
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	114746	1195653.32	52276254	06/22/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common	12/15/2020	Acquired from issuer in private transaction	Issuer			114746	12/15/2020	None

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	06/01/2026	1922	19257.86

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 01/09/2026 that is intended to comply with Rule 10b5-1(c).
Date of Notice	06/22/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	01/09/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of David Kirn
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)